$CPRX 10-bagger corrected $1.25 Nasdaq GM Web
Post# of 63824
Posted On: 09/25/2016 9:01:58 PM
$CPRX 10-bagger corrected $1.25
Nasdaq GM
Website
Shares Outstanding 82.87M
Float 56.73M
% Held by Insiders 16.60%
% Held by Institutions 53.90%
Shares Short 2.02M
Short Ratio 1.98
Short % of Float 2.62%
Shares Short (prior month) 1.8M
Headlines
and Filings
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of MuSK-antibody positive myasthenia gravis. The company also develops CPP-115, a GABA aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy and other neurological indications, such as complex partial seizures and Tourettes disorder; and CPP-109 to treat Tourettes disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Nasdaq GM
Website
Shares Outstanding 82.87M
Float 56.73M
% Held by Insiders 16.60%
% Held by Institutions 53.90%
Shares Short 2.02M
Short Ratio 1.98
Short % of Float 2.62%
Shares Short (prior month) 1.8M
Headlines
and Filings
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of MuSK-antibody positive myasthenia gravis. The company also develops CPP-115, a GABA aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy and other neurological indications, such as complex partial seizures and Tourettes disorder; and CPP-109 to treat Tourettes disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
(0)
(0)